| アブストラクト | INTRODUCTION: The use of incretin-based drugs may be associated with a decreased risk of endometrial cancer among women with type 2 diabetes. METHODS: Using data from the UK Clinical Practice Research Datalink and linked databases, two new-user active comparator cohorts of women with type 2 diabetes who initiated glucagon-like peptide 1 receptor agonists (GLP-1 RAs) or sulfonylureas (cohort 1) and DPP-4 inhibitors or sulfonylureas (cohort 2) were assembled. Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident endometrial cancer. RESULTS: Cohort 1 included 9239 new users of GLP-1 RAs and 80,086 new users of sulfonylureas. The GLP-1 RAs were not associated with a decreased risk of endometrial cancer when compared with sulfonylureas (HR: 1.11, 95% CI: 0.66-1.88). In a duration-response secondary analysis, use of GLP-1 RAs for more than two years was associated with an increased risk of endometrial cancer (HR: 2.47, 95% CI: 1.37-4.43) when compared to sulfonylureas When analysed by drug type, exenatide was associated with an elevated risk when compared to sulfonylureas (HR: 2.26, 95% CI:1.06-4.82). Cohort 2 included 42,486 new users of DPP-4 inhibitors and 79,353 new users of sulfonylureas. DPP-4 inhibitors were not associated with a decreased risk of endometrial cancer compared with sulfonylureas (HR: 1.00, 95% CI: 0.76-1.32). In a duration-response secondary analysis, use of DPP-4 inhibitors for more than two years was associated with an increased risk of endometrial cancer (HR: 1.63, 95% CI: 1.14-2.33) when compared to sulfonylureas. CONCLUSIONS: In this population-based study, the use of GLP-1 RAs and DPP-4 inhibitors was not associated with a decreased risk of endometrial cancer when compared with the use of sulfonylureas among women with type 2 diabetes. |
|---|
| 組織名 | Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;3755 Cote Sainte-Catherine, H425.1, Montreal, Quebec, H3T 1E2, Canada.;Department of Epidemiology, and Occupational Health, McGill University,;BiostatisticsMontreal, QC, H3A 1G1, Canada.;Division of Endocrinology, Jewish General Hospital, Montreal, QC, H3T 1E2,;Canada.;Division of Endocrinology and Metabolism, McGill University, Montreal, QC, H4A;3J1, Canada.;Division of Experimental Medicine, Lady Davis Institute of Medical Research,;Jewish General Hospital, McGill University, Montreal, QC, H3T 1E2, Canada.;Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, H4A 3T2,;laurent.azoulay@mcgill.ca.;BiostatisticsMontreal, QC, H3A 1G1, Canada. laurent.azoulay@mcgill.ca.;Canada. laurent.azoulay@mcgill.ca. |
|---|
